Key Developments: Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

650.55INR
6:28am EDT
Price Change (% chg)

Rs-5.05 (-0.77%)
Prev Close
Rs655.60
Open
Rs656.90
Day's High
Rs663.00
Day's Low
Rs647.85
Volume
128,863
Avg. Vol
219,133
52-wk High
Rs663.00
52-wk Low
Rs366.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cipla Ltd Managing Director To Retire
Wednesday, 6 Feb 2013 06:21am EST 

Cipla Ltd announced that Dr. Y K Hamied has expressed his desire to retire as Managing Director of the Company. The Board unanimously has accepted his proposal to retire as Managing Director effective March 31, 2013. Dr .Hamied, however continues to be the Chairman of the Company in a non-executive role effective April 01, 2013.  Full Article

Cipla Ltd Gains On Partner's Contract Win-Business Standard
Friday, 30 Nov 2012 02:49am EST 

Business Standard reported that Cipla Ltd's Cipla Medpro won a share in South Africa's $667 million contract, as it supplies the bulk of Cipla Medpro's drugs. South Africa on Thursday awarded a $667 million contract to supply life-prolonging HIV medicine to 12 international and domestic firms, including Cipla Medpro, to deal with its biggest health problem.  Full Article

Cipla Ltd Announces Appointment Of Chief Executive Officer
Wednesday, 21 Nov 2012 09:37pm EST 

Cipla Ltd announced the appointment of Mr. Subhanu Saxena as Chief Executive Officer.  Full Article

Cipla Ltd To Buy Control Of Cipla Medpro South Africa Ltd-Economic Times
Tuesday, 20 Nov 2012 04:40pm EST 

Economic Times reported that Cipla Ltd has offered to buy a about a 51% stake in Cipla Medpro South Africa Ltd. The Indian firm has offered ZAR8.55 per share, Cipla Medpro said in a statement. The price represents an 11% premium on Cipla Medpro's closing share price on November 20, 2012.  Full Article

Photo

Cipla asks India to revoke Novartis patents on respiratory drug

MUMBAI - Generic drugmaker Cipla Ltd said on Thursday it has asked the Indian government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Onbrez and has launched a cheaper copy to boost access in the local market.

Search Stocks